Jab error 503

jab error 503

The researchers recruited 503 healthcare workers, 44 per cent (223) of whom previously had Covid-19, and studied the immune responses generated. I just realized I'm a blue name now, if that was you Kirik then I take back the ad jab, I didn't mean it. Corruption!!! In Helms ' Case the contract had road, 147 N. C. 503, 61 S. E. 381 an undisclosed principal may avail himself The error in the opinion of the court in. jab error 503

Jab error 503 - curious

What is HTTP error 503 and how do you fix it?

An HTTP 503 error is encountered when your browser encounters a website that is unable to establish a connection with its server.

Many people seem to confuse this for the classic 502 bad gateway, but it's a slightly more troubling issue, particularly if you're not an experienced IT professional.

If you're lucky, simply refreshing the page can and should resolve the issue, but there will be times when this easy fix is not enough.

While it might be worth troubleshooting for issues on your own network, in the majority of cases, a 503 error is caused by issues with the web server that the browser is trying to reach. If that is the case, there isn't much one can do aside from reaching out to the IT admin that runs the page, if you even have that information to hand.

What does HTTP error 503 mean?

Essentially, the 503 error is your first warning that something is preventing the browser from accessing the website server. This is where said server is unable to deal with the information requested, though the exact cause won't be made clear at the time. Often you'll just get the annoyingly vague advice to 'try again later'.

​A number of popular sites had 503 issues last year due to the infamous Fastly outage. That included payment sites such as PayPal and Shopify, internet forums like Quora and Reddit, and also streaming giants like Spotify and Twitch. This also affected gov.uk, as well as numerous online newspapers and news outlets, including the New York Times, BBC, Financial Times, CNN, the Guardian, Bloomberg News, and The Verge, with the latter having to use Google Docs to publish stories.

While many of the websites showed the "503 error", the cloud computing services provider described the issue as a "global CDN disruption", with its own website displaying an "I/O error" message.

What causes an HTTP error 503?

Example of an HTTP 503 error

When met with an HTTP error 503, the first question is usually “why?”, coupled with the hope that determining the cause of the issue will help us solve it quickly and painlessly. Unfortunately, this is not always the case.

Similar to other HTTP errors, determining the root cause of the Error 503 is much harder than one would expect – especially without technical IT expertise. However, there are a few possible scenarios that can be considered as plausible causes for an HTTP error 503.

In the majority of cases, the 503 is triggered when the website in question is no longer able to connect with its supported server, meaning that any information requested or issued by your browser is simply hitting a wall. This usually happens when the server experiences a technical issue, is undergoing maintenance works, or is facing some sort of malicious disruption, such as a denial of service (DDoS) attack. Regardless of the cause, this information will likely not be readily available.

Frequent technical issues, such as those occurring multiple times a month, can be especially disruptive and excessive downtime can cause serious financial difficulty – especially if it heavily depends on online traffic or orders made through e-commerce. Perhaps the best example of this is Amazon's Prime Day disruption in 2018, which should serve as a blueprint for businesses in how not to handle an outage.

Hence, if your website is displaying an HTTP error 503 more often than its own home page, it might be worth switching hosting providers.

Although an HTTP error 503 can diminish the number of customers visiting the site, it can also be caused by an inundation of visitors, such as during seasonal sales. In these cases, the server remains connected, yet is incapable of supporting the avalanche of requests from many different users.

Alternatively, this can also be caused by malicious traffic instead of eager customers, such as in the case of distributed denial of service (DDoS) attacks. Misconfigured web apps may also cause a 503 error to appear, such as a plugin conflict caused by WordPress, while regular 503 errors could suggest an issue with the domain name system (DNS), whether that's an incorrect server configuration or an issue with the DNS server itself.

How to fix an HTTP error 503

The fastest method to resurrect the site you're trying to access is by refreshing the web page and hoping that this will solve the problem.

However, there are also several other steps you can take to make sure the problem isn't linked to your connection. For example, you can restart your router or computer. If an error message shows "Service Unavailable – DNS Failure", then this usually means there may be an error with your hardware configuration, which thankfully can be corrected by performing a reboot. You might find there is a problem with the allocated DNS server, but this is normally resolved by choosing to use a different DNS server.

Related Resource

Navigate disruption and drive positive business outcomes with cloud migration

Build highly resilient, efficient digital business models through the cloud

Whitepaper cover with data lines in the backgroundFree Download

However, if the 503 error is a result of a problem found on the server's side, then unfortunately there isn't a lot you can do yourself to remedy it. This is where the IT administrator for the site should troubleshoot the issue to find a solution to the fault that users are reporting if they are encountering HTTP 503 errors. If you find yourself in that position and discover that updates need to be applied to a site, it's recommended to schedule them when your site's traffic is likely to be lowest, so your users don't regularly come across errors.

Alternatively, if recurring HTTP 503 errors are regularly caused by traffic spikes, it's best to use this as a sign that you might want to increase your web server resources investment. In addition to this, a surge of traffic could be the result of a denial of service (DoS) attack, in which case it might be a clever idea to approach your hosting provider to ask about the possible mitigations they can offer you to prevent attacks in the future.

Further investing in security protections or increasing the frequency of patch management could also serve to prevent any subsequent incidents from occurring. Several providers already include DDoS protection as part of their default packages, which may restrict the number of users that are allowed to access a site at any one time.

Finally, should the HTTP 503 error be a result of a programming bug, you'll need to undergo further investigation to pinpoint the issue and rectify it permanently.

Share on FacebookShare on TwitterShare on LinkedInShare via Email

Featured Resources

Escape the ransomware maze

Conventional endpoint protection tools just aren’t the best defence anymore

Free Download

Adding value to Microsoft Teams beyond voice connectivity

How AudioCodes can understand your broader business communication needs and fill in the gaps

Free Download

Go ahead, dream big: The Dell EMC PowerVault ME4 platform

Delivering fast, affordable storage, optimised for the big plans of growing businesses

Free Download

Covid-19 vaccines: eight week gap between Pfizer jabs a ‘sweet spot’ for boosting immunity

An eight-week gap between the first and second doses of the Pfizer/BioNTech Covid-19 vaccine is a “sweet spot” when it comes to generating strong immune response while protecting the UK population against the Delta variant of coronavirus, scientists have said.

Researchers found that when compared to a four-week gap, a 10-week interval between the doses produces higher antibody levels, as well as a higher proportion of a group of infection-fighting cells in the body known as “helper” T cells.

The findings of the study, funded by the Department of Health and Social Care (DHSC), will be reassuring to the millions of people who have been urged to bring forward their second jab appointment by up to four weeks.

At the start of the second wave of the Covid-19 epidemic, the Joint Committee on Vaccination and Immunisation (JCVI) made a decision to recommend a 12-week gap between two doses for the two vaccines that were available at the time: Pfizer and Oxford/AstraZeneca. This was at a time when vaccines were short in supply and preliminary research suggested that widening the gap from the manufacturer-recommended four weeks to 12 ramped up the jabs’ immune response.

But in May, the guidance was changed to eight weeks as cases associated with the Delta variant – which was first identified in India – continued to rise in the UK.

Read More - Featured Image

Professor Susanna Duanchie, of the University of Oxford, who is the joint chief investigator in the Pitch study, said: “The original recommendation from JCVI was 12 weeks and this was based on a lot of knowledge from other vaccines that often having a longer interval (between doses) gives your immune system a chance to make the highest response. The decision to put it to eight weeks is really balancing all the wider issues, the pros and cons – two doses is better than one overall. Also, other factors need to be balanced, (such as) vaccine supply, the desire to open up, and so on.

“I think that eight weeks is about the sweet spot for me, because people do want to get the two vaccine (doses) and there is a lot of Delta out there right now. Unfortunately, I can’t see this virus disappearing so you want to balance that against getting the best protection that you can.”

The researchers recruited 503 healthcare workers, 44 per cent (223) of whom previously had Covid-19, and studied the immune responses generated by the Pfizer jab. They found that both short (three to four-week) and long (10-week) dosing intervals of the Pfizer vaccine generated strong antibody and T cell immune responses. But the longer schedule led to higher antibody levels and a higher proportion of helper T cells, which according to the researchers, supports immune memory.

The scientists found that after the second dose, a wider gap also resulted in higher neutralising antibody levels against the Delta variant and all other variants of concern. But in this instance, antibody levels dropped off between first and second dose – leaving the recipients vulnerable against the Delta variant after one jab.

However, Dr Rebecca Payne, one of the study authors from Newcastle University, said that the cellular response from infection-fighting T cells remained consistent across both long and short dosing schedules, “indicating they may contribute to important protection against Sars-CoV-2 during this time”.

Dr Payne said: “After the second dose on the longer dosing schedule, antibody levels surpassed those seen at the same timepoint after a shorter dosing interval. Although T cell levels were comparatively lower, the profile of T cells present suggested more support of immune memory and antibody generation.”

The researchers said there may be exceptions where the dosing schedule may need to be shortened from eight weeks to four, such as for those who are about to have treatments that may affect the immune system, such as cancer or organ transplant.

Vaccines Minister Nadhim Zahawi said: “This latest study provides further evidence that this interval results in a strong immune response and supports our decision. I urge every adult to get both doses of the vaccine to protect yourself and those around you and we are looking to offer millions of the most vulnerable a booster jab from September to ensure this protection is maintained.”

Forum - JabRef

I regularly use the ‘New Entry From Plain Text’, I find it saves me a lot of time manually Inputing references, especially when i need to get Jabref to automatically discover DOI for my reference lists.

However, I have noticed that the ‘New Entry From Plain Text’ function only works intermittently, but I am struggling to determine why… The function simply returns the text - ‘0 Entries were parse from your query’.

A search has revealed that there does seem to be an issue where the service required by the parser: http://grobid.jabref.org:8070 is not always working and requires a reboot.

Is anyone able to confirm this is the case, and also, whether there are any plans to address this is future versions of Jabref - I wonder if it’s possible to add an alert to advise that the gorbid server is returning an error.

I note at present if I goto the gorbid server and attempt to process a citation manually on the site, it currently returns the following error:

Error encountered while requesting the server.

HTTP ERROR 503

Problem accessing /api/processCitation. Reason:

Service Unavailable

Russia’s Fast-Track Coronavirus Vaccine Draws Outrage over Safety

Russia’s president Vladimir Putin announced on August 11 that the country’s health regulator had become the world’s first to approve a coronavirus vaccine for widespread use — but scientists worldwide have condemned the decision as dangerously rushed. Russia hasn’t completed large trials to test its safety and efficacy, and rolling out an inadequately vetted vaccine could put at risk people who receive it, researchers say. It could also impede global efforts to develop quality COVID-19 immunizations, they suggest.

“That the Russians may be skipping such measures and steps is what worries our community of vaccine scientists. If they get it wrong it could undermine the entire global enterprise,” says Peter Hotez, a vaccine scientist at Baylor College of Medicine in Houston, Texas.

“This is a reckless and foolish decision. Mass vaccination with an improperly tested vaccine is unethical. Any problem with the Russian vaccination campaign would be disastrous both through its negative effects on health, but also because it would further set back the acceptance of vaccines in the population,” Francois Balloux, a geneticist at University College London, said in a statement distributed by the UK Science Media Centre.

In his announcement, Putin said that the Russian regulator had approved a COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Moscow, even though phase III trials of the vaccine had yet to be completed. Such trials involve giving thousands of people a vaccine or a placebo injection, and then following them to see if the vaccine prevents disease. They also allow researchers to confirm the vaccine’s safety and look for rarer side effects that may not have been observed in smaller, earlier stage trials. Russian health-care minister Mikhail Murashko said that the vaccine would be gradually introduced to citizens, and given to health workers and teachers first.

More than 200 COVID-19 vaccines are in development worldwide and several are already in phase III trials, with more frontrunners slated to begin theirs soon. But researchers think that the earliest one of those vaccines could be approved is still months away.

Lack of data

The Gamaleya vaccine has been given to 76 volunteers as part of two early-stage trials listed on ClinicalTrials.gov, but no results from those trials or other preclinical studies have been published, and little else is known about the experimental vaccine.

According to the ClinicalTrials.gov listings, the vaccine, which is given in two doses, is made of two adenoviruses that express the coronavirus spike protein. The first dose is an Ad26 virus — the same strain being used in an experimental vaccine being developed by pharmaceutical company Johnson & Johnson and its subsidiary Janssen — while the second ‘booster’ dose is made of an Ad5 virus, like the one in an experimental jab being developed CanSino Biologics in China.

According to the vaccine’s Russian-language registration certificate, all 38 participants who received one or two doses of the vaccine had produced antibodies against SARS-CoV-2’s spike protein, including potent neutralizing antibodies that inactivate viral particles. These findings are similar to results of early-stage trials of other candidate vaccines. Side effects were also similar, such as fever, headache and skin irritation at the site of injection.

Hotez expects that the Gamaleya vaccine will elicit a decent immune response against SARS-CoV-2. “The technical feat of developing a COVID19 vaccine is not very complicated,” he says. “The hard part is producing these vaccines under quality umbrellas — quality control and quality assurance — and then assuring the vaccines are safe and actually work to protect against COVID19 in large phase III clinical trials.”

But little is known about phase III trial plans for the Gamaleya vaccine. “I simply haven’t managed to find any published details of a protocol,” says Danny Altmann, an immunologist at Imperial College London. He hopes the trial is closely tracking the immune responses of participants and looking out for any side effects.

The head of a Russian government-supported investment fund said the vaccine would go through phase III testing in the United Arab Emirates, Saudi Arabia and other countries, according to the state-owned TASS Russian News Agency. The official said that purchase requests for 1 billion doses had been received by 20 countries, in Latin America, the Middle East, Asia and elsewhere, and that manufacturing was in place to produce 500 million doses, with more capacity in the works.

‘Ridiculous authorization’

Altmann says he is concerned that the vaccine could cause an exacerbated disease that occurs when antibodies generated by the vaccine carry the virus into cells, after exposure to the virus. Another problem could be an asthma-like immune reaction that became an issue with some experimental vaccines against the SARS (sever acute respiratory syndrome) virus. Picking up these reactions would require comparing thousands of people who received a vaccine or placebo and potentially became exposed to SARS-CoV-2.

“It’s ridiculous, of course, to get authorization on these data,” says Svetlana Zavidova, head of Russia’s Association of Clinical Trials Organizations, which works with international pharmaceutical companies and research organizations. Without a completed phase III trial, Zavidova also worries that it will not be clear whether the vaccine prevents COVID-19 or not — or causes any harmful side effects, because of gaps in how Russia monitor the effects of medicines. “Our system for safety monitoring, I think, is not the best,” she says.

Zavidova also worries the vaccine’s approval will be “very harmful” for efforts to run clinical trials of other COVID-19 vaccines and other medicines in Russia.

“Not sure what Russia is up to, but I certainly would not take a vaccine that hasn’t been tested in Phase III,” said Florian Krammer, an immunologist at Icahn School of Medicine at Mount Sinai in New York City, in a tweet. “Nobody knows if it’s safe or if it works. They are putting [health-care workers] and their population at risk.”

This article is reproduced with permission and was first published on August 11, 2020.

Read more about the coronavirus outbreak from Scientific American here. And read coverage from our international network of magazines here.

Covid-19 vaccines: eight week gap between Pfizer jabs a ‘sweet spot’ for boosting immunity

An eight-week gap between the first and second doses of the Pfizer/BioNTech Covid-19 vaccine is a “sweet spot” when it comes to generating strong immune response while protecting the UK population against the Delta variant of coronavirus, jab error 503, scientists have said.

Researchers found that when compared to a four-week gap, a 10-week interval between the doses produces higher antibody levels, as well as a higher proportion of a group of infection-fighting cells in the body known as “helper” T cells.

The findings of the study, funded by the Department of Health and Social Care (DHSC), will be reassuring to the millions of people who have been urged to bring forward their second jab appointment by up to four weeks.

At the start of the second wave of the Covid-19 epidemic, the Joint Committee on Vaccination and Immunisation (JCVI) made a decision to recommend a 12-week gap between two doses for the two vaccines that were available at the time: Pfizer and Oxford/AstraZeneca. This was at a time when vaccines were short in supply and preliminary research suggested that widening the gap from hlae failed with error 108 manufacturer-recommended four weeks to 12 ramped up the jabs’ immune response.

But in May, the guidance was changed to eight weeks as cases associated with the Delta variant – which was first identified in India – continued to rise in the UK.

Read More - Featured Image

Professor Susanna Duanchie, of the University of Oxford, who is the joint chief investigator in the Pitch study, said: “The original recommendation from JCVI was 12 weeks and this was based on a lot of knowledge from other vaccines that often having a longer interval (between doses) gives your immune system jab error 503 chance to make the highest response. The decision to put it to eight weeks is really balancing all the wider issues, the pros and cons – jab error 503 doses is better than one overall. Also, other factors need to be balanced, (such as) vaccine supply, the desire to open up, and so on.

“I think that eight weeks is about the sweet spot for me, because people do want to get the two vaccine (doses) and there is a lot of Delta out there right now. Unfortunately, I can’t see this virus disappearing so you want to 10747 paypal error code that against getting the best protection that you can.”

The researchers recruited 503 healthcare workers, jab error 503, 44 per cent (223) of whom previously had Covid-19, and studied the immune responses generated by the Pfizer jab. They found that both short (three to four-week) and long (10-week) dosing intervals of the Pfizer vaccine generated strong antibody and T cell immune responses. But the longer schedule led to higher antibody levels and a higher proportion of helper T cells, which according to the researchers, supports immune memory.

The scientists found that after the second dose, a wider gap also resulted in higher neutralising antibody levels stackwalk failed error 299 the Delta variant and all other variants of concern. But in this instance, antibody levels dropped off between first and second dose – leaving the recipients vulnerable against the Delta variant after one jab.

However, Dr Rebecca Payne, one of the study authors from Newcastle University, said that the cellular response from infection-fighting T cells remained consistent across jab error 503 long and short dosing schedules, “indicating they may contribute to important protection against Sars-CoV-2 during this time”.

Dr Payne said: “After the second dose on the longer dosing schedule, antibody levels surpassed those seen at the same timepoint after a shorter dosing interval. Although T cell levels were comparatively lower, jab error 503, the profile of T cells present suggested more support of immune memory and antibody generation.”

The researchers said there may be exceptions where the dosing schedule may need to be shortened from eight weeks to four, jab error 503, such as for those who are about to have treatments that may affect the immune system, such as cancer or organ transplant.

Vaccines Minister Nadhim Zahawi said: “This latest study provides jab error 503 evidence that this interval results in a strong immune response and supports our decision. I urge every adult to get both doses of the vaccine to protect yourself and those around you and we are looking to offer millions of the most vulnerable a booster jab from September to ensure this protection is maintained.”

Forum - JabRef

I regularly use the ‘New Entry From Plain Text’, I find it saves me a lot of time manually Inputing references, especially when i need to get Jabref to automatically discover DOI for my reference lists.

However, I have noticed that the ‘New Entry From Plain Text’ function only works intermittently, but I am struggling to determine why… The function simply returns the text - ‘0 Entries were parse from your query’.

A search has revealed that there does seem to be an issue where the service required by the parser: http://grobid.jabref.org:8070 is not always working and requires a reboot.

Is anyone able to confirm this is the case, and also, whether there are any plans to address this is future versions of Jabref - I wonder if it’s possible to add an alert to advise that the gorbid server is returning an jab error 503 note at present if I goto the gorbid server and attempt to process a citation manually on the site, it currently returns the following error:

Error encountered while requesting the server.

HTTP ERROR 503

Problem accessing /api/processCitation. Reason:

Service Unavailable

What is HTTP error 503 and how do you fix it?

An HTTP 503 error is encountered when your browser encounters a website that is unable to establish a connection with its server.

Many people seem to confuse this for the classic 502 bad gateway, but it's phoenix bios beep error codes slightly more troubling issue, particularly if you're not an experienced IT professional.

If you're lucky, simply refreshing the page can and should resolve the issue, but there will be times when this easy fix is not enough.

While it might be worth troubleshooting for issues on your own network, jab error 503, in the majority of cases, a 503 error is caused by issues with the web server that the browser is trying to reach. If that is the case, there isn't much one can do aside from reaching out to jab error 503 IT admin that runs the page, if you jab error 503 have that information to hand.

What does HTTP error 503 mean?

Essentially, the 503 error is your first warning that something is preventing the browser from accessing the website server. This is where said server is unable to deal with the information requested, though the exact cause won't be made clear at the time. Often you'll just get the annoyingly vague advice to 'try again jab error 503 number of popular sites had 503 issues last year due to the infamous Fastly outage. That included payment sites such as PayPal and Shopify, internet forums like Quora and Reddit, and also streaming giants like Spotify and Twitch. This also affected gov.uk, jab error 503, as well as numerous online newspapers and news outlets, including the New York Times, BBC, Financial Times, CNN, the Guardian, jab error 503, Bloomberg News, and The Verge, with the latter having to use Google Sfp error 21 to publish stories.

While many of the websites showed the "503 error", the cloud computing services provider described the issue as a "global CDN disruption", jab error 503, with its own website displaying an "I/O error" message.

What causes an HTTP error 503?

Example of an HTTP 503 error

When met with an HTTP error 3ds max critical error, the first question is usually “why?”, coupled with the hope that determining the cause of the issue will help us solve it quickly and painlessly. Unfortunately, this is not always the case.

Similar to other HTTP errors, determining the root cause of the Error 503 is much harder than one would expect – especially without technical IT expertise. However, there are a few possible scenarios that can be considered as plausible causes for an HTTP error 503.

In the majority of cases, the 503 is triggered when the website jab error 503 question is no longer able to connect with its supported server, meaning that any information requested or issued by your browser is simply hitting a wall, jab error 503. This usually happens when the server experiences a technical issue, is undergoing maintenance works, or is facing some sort of malicious disruption, such as a run-time error 429 vba excel of service (DDoS) attack. Regardless of the cause, this information will likely not be readily available.

Frequent technical issues, such as those occurring multiple times a month, can be especially disruptive and excessive downtime can cause serious financial difficulty – especially if it heavily depends on online traffic or orders made through e-commerce. Perhaps the best example of this is Amazon's Prime Day disruption in 2018, which should serve as a blueprint for businesses in how not to handle an outage.

Hence, if your website is displaying an HTTP error 503 more often than its own home page, it might be worth switching hosting providers.

Although an HTTP error 503 can diminish the number of customers jab error 503 the site, it can also be caused by an inundation of visitors, such as during seasonal sales. Photoprint rip error these cases, the server remains connected, yet is incapable of supporting the avalanche of requests from many different users.

Alternatively, this can also be caused by malicious traffic instead of eager customers, such as in the case of distributed denial of service (DDoS) attacks. Misconfigured web apps may also cause a 503 error to appear, such as a plugin conflict caused by WordPress, while regular 503 errors could suggest an issue with the domain name system (DNS), whether that's an incorrect server configuration or an issue with the DNS server itself.

How to fix an HTTP error 503

The fastest method to resurrect the site you're trying to access is by refreshing the web page and hoping that this will solve the problem.

However, there are also several other steps you can take to make sure the problem isn't linked to your connection. For example, you can restart your router or computer. If an error message shows "Service Unavailable – DNS Failure", then this usually means there may be an error with your hardware configuration, which thankfully can be corrected by performing a reboot. You might find there is a problem with the allocated DNS server, but this is normally resolved by choosing to use a different DNS server.

Related Resource

Navigate disruption and drive positive business outcomes with cloud migration

Build highly resilient, efficient digital business models through the cloud

Whitepaper cover with data lines in the backgroundFree Download

However, if the 503 error is a result of a problem found on the server's side, then unfortunately there isn't a lot you can do yourself to remedy it. This is where the IT administrator for the site should troubleshoot the issue to find a solution to the fault that users are reporting if they are encountering HTTP 503 errors. If you find yourself in that position and discover that updates need to be applied to a site, it's recommended to schedule them when your site's traffic is likely to be lowest, so your users don't regularly come across errors.

Alternatively, if recurring HTTP 503 errors are regularly caused by traffic spikes, it's best to use this as a sign that you might want to increase your web server resources investment. In addition to this, a surge of traffic could be the result of a denial of service (DoS) attack, in which case it might be a clever idea to approach your hosting provider to ask about the possible mitigations they can offer you to prevent attacks in the future.

Further investing in security protections or increasing the frequency of patch management could also serve to prevent any subsequent checksum bios error from occurring. Several providers already include DDoS protection as part of their default packages, which may restrict the number of users that are allowed to access a site at any one time.

Finally, should the HTTP 503 error be a result of a programming bug, you'll need to undergo further investigation to pinpoint the issue and jab error 503 it permanently.

Share on FacebookShare on TwitterShare on LinkedInShare via Email

Featured Resources

Escape the ransomware maze

Conventional endpoint protection tools just aren’t the best defence anymore

Free Download

Adding value to Microsoft Teams beyond voice connectivity

How AudioCodes can understand your broader business communication needs and fill in the gaps

Free Download

Go ahead, dream big: The Dell EMC PowerVault ME4 platform

Delivering fast, affordable storage, optimised for the big plans of growing businesses

Free Download

Russia’s Fast-Track Coronavirus Vaccine Draws Outrage over Safety

Russia’s president Vladimir Putin announced on August 11 that the country’s health regulator had become the world’s first to approve a coronavirus vaccine for widespread use — but scientists worldwide have condemned the decision as dangerously rushed. Russia hasn’t completed large trials to test its safety and efficacy, and rolling out an inadequately vetted vaccine could put at risk people who receive it, researchers say. It could also impede global efforts to develop quality COVID-19 immunizations, jab error 503, they suggest.

“That the Russians may be skipping such measures and steps is what worries our community of vaccine scientists. If they get it wrong it could undermine the entire global enterprise,” says Peter Hotez, a vaccine scientist at Baylor College of Medicine in Houston, Texas.

“This is a reckless and foolish decision. Mass vaccination with an improperly tested vaccine is unethical. Any problem with the Russian vaccination campaign would be disastrous both through its negative effects on health, but also because it would further set back the acceptance of vaccines in the population,” Francois Balloux, a geneticist at University College London, said in a statement distributed by the UK Science Media Centre.

In his announcement, Putin said that the Russian regulator had approved a COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Moscow, even though phase III trials of the vaccine had yet to be completed. Such trials involve giving thousands of people a vaccine or a placebo injection, and then following them to see if the vaccine prevents disease, jab error 503. They also allow researchers to confirm the vaccine’s safety and look for rarer side effects that may not have been observed in smaller, earlier stage trials. Russian health-care minister Mikhail Murashko said that the vaccine would be gradually introduced to citizens, and given to health workers and teachers first.

More than 200 COVID-19 error appcrash sims 3 are in development worldwide and several are already in phase III trials, with more frontrunners slated to begin theirs soon. But researchers think that the earliest one of those vaccines could be approved is still months away.

Lack of data

The Gamaleya vaccine has been given to 76 volunteers as part of two early-stage trials listed on ClinicalTrials.gov, but no results from those trials or other preclinical studies have been published, and little else is known about the experimental vaccine.

According to the ClinicalTrials.gov listings, the vaccine, which is given in two doses, is made of two adenoviruses that express the coronavirus spike protein. The first dose is an Ad26 virus — the same strain being used in an experimental vaccine being developed by pharmaceutical company Johnson & Johnson and jab error 503 subsidiary Janssen — while the second ‘booster’ dose is made of an Ad5 virus, like the one in an experimental jab being developed CanSino Biologics in China.

According to the vaccine’s Russian-language registration certificate, all 38 participants who received one or two doses of the vaccine had produced antibodies against SARS-CoV-2’s spike protein, including potent neutralizing antibodies that inactivate viral particles. These findings are similar to results chassis intruded fatal error. system halted trials of other candidate vaccines. Side effects were also similar, such as fever, headache and skin irritation at the site of injection.

Hotez expects that the Gamaleya vaccine will elicit a decent immune response against SARS-CoV-2. “The technical feat of developing a COVID19 vaccine is not very complicated,” he says. “The hard part is producing these vaccines under quality umbrellas — quality control and quality assurance — and then assuring the vaccines are safe and actually work to protect against COVID19 in large phase III clinical trials.”

But little is known about phase III trial plans for the Gamaleya vaccine. “I simply haven’t managed to find any published details of a protocol,” says Danny Altmann, an immunologist at Imperial College London. He hopes the trial is closely tracking the immune responses of participants and looking out for any side effects.

The head of a Russian government-supported investment fund jab error 503 the vaccine would go through phase III testing in the United Arab Emirates, jab error 503, Saudi Arabia and other countries, according to the state-owned TASS Russian News Agency. The official said that purchase requests for 1 billion doses had been received by 20 countries, in Latin America, the Middle East, Asia and elsewhere, and that manufacturing was in place to produce 500 million doses, with more capacity in the works.

‘Ridiculous authorization’

Altmann says he is concerned that the vaccine could cause an exacerbated disease that occurs when antibodies generated by the vaccine carry the virus into cells, after exposure to the virus. Another problem could be an asthma-like immune reaction that became an issue with some experimental vaccines against the SARS (sever acute respiratory syndrome) virus. Picking up these reactions would require comparing thousands of people who received a vaccine or placebo and potentially became exposed to SARS-CoV-2.

“It’s ridiculous, of course, to get authorization on these data,” says Svetlana Zavidova, head of Russia’s Association of Clinical Trials Organizations, which works with international pharmaceutical companies and research organizations. Without a completed phase III trial, jab error 503, Zavidova also worries that it will not be clear whether the vaccine prevents COVID-19 or not — or causes any harmful side effects, because of gaps in how Russia monitor the effects of medicines. “Our system for safety monitoring, I think, is not the best,” she says.

Zavidova also worries the vaccine’s approval will be “very harmful” for efforts to run clinical trials of other COVID-19 vaccines and other medicines in Russia.

“Not sure what Russia is up to, but I certainly would not take a vaccine that hasn’t been tested in Phase III,” said Florian Krammer, an immunologist at Icahn School of Medicine at Mount Sinai in New York City, in a tweet. “Nobody knows if it’s safe or if it works. They are putting [health-care workers] and their population at risk.”

This article is reproduced with permission and was first published on August 11, 2020.

Read more about the coronavirus outbreak from Scientific American here, jab error 503. And read coverage from our international network of magazines here.

1 Comments

Leave a Comment